Takeda's Millennium, Infinity Restructure Oncology Drug License
This article was originally published in PharmAsia News
Takeda's Millennium oncology arm and Infinity Pharmaceuticals have restructured a licensing agreement involving Infinity's IPI-145 drug for treating blood cancer.
You may also be interested in...
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.